Oncology Research and Treatment
Original Article
NORAD Expression Is Associated with Adverse Prognosis in Esophageal Squamous Cell CarcinomaWu X.a-c · Lim Z.-F.c · Li Z.d · Gu L.a,e · Ma W.a · Zhou Q.a · Su H.a · Wang X.a · Yang X.f · Zhang Z.a,ga State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China; b Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China; c WVU Cancer Institute, Mary Babb Randolph Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia, U.S.A.; d Department of Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China; e Puer University, Puer, China; f Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China; g Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 24, 2017
Accepted: February 24, 2017
Published online: May 10, 2017
Issue release date: June 2017
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 2
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Summary
Background: NORAD (non-coding RNA-activated by DNA damage) is a conserved, abundant, and broadly expressed long non-coding RNA, which functions to preserve genome stability. However, its prognostic significance in esophageal squamous cell carcinoma (ESCC) remains unclear. Material and Methods: The expression of NORAD was detected by quantitative real-time polymerase chain reaction in pairs of tumorous and adjacent normal tissues derived from 106 ESCC patients. We analyzed the potential relationship between NORAD expression levels in tumor tissues and clinicopathological features of ESCC patients and clinical outcome. Results: The relative expression levels of NORAD were significantly upregulated in tumor tissues (p < 0.001) compared to adjacent normal tissues. In addition, high expression of NORAD was correlated with larger tumor size (p = 0.021) and T stage (p = 0.045). Kaplan-Meier analysis indicated that patients with high NORAD expression had poor overall and disease-free survival (p < 0.001). Moreover, multivariate analysis showed that increased expression of NORAD was an independent predictor of overall survival (p = 0.001). Conclusion: Our data indicate that increased NORAD expression might serve as a novel molecular predictor of poor prognosis in ESCC patients and maybe a potential target for diagnosis and gene therapy.
© 2017 S. Karger GmbH, Freiburg
Related Articles:
References
-
Wu CC, Chen CJ: Esophageal carcinoma. N Engl J Med 2015;372:1472.
-
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL, Taylor PR: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005;113:456-463.
-
Ulitsky I, Bartel DP: lincRNAs: genomics, evolution, and mechanisms. Cell 2013;154:26-46.
-
Li CH, Chen Y: Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 2013;45:1895-1910.
-
Thum T, Fiedler J: LINCing MALAT1 and angiogenesis. Circ Res 2014;114:1366-1368.
-
Wapinski O, Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol 2011;21:354-361.
-
Rinn JL, Chang HY: Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012;81:145-166.
-
Tichon A, Gil N, Lubelsky Y, Havkin Solomon T, Lemze D, Itzkovitz S, Stern-Ginossar N, Ulitsky I: A conserved abundant cytoplasmic long noncoding RNA modulates repression by Pumilio proteins in human cells. Nat Commun 2016;7:12209.
-
Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011;6:1984-1992.
-
Liu J, Peng WX, Mo YY, Luo D: MALAT1-mediated tumorigenesis. Front Biosci (Landmark Ed) 2017;22:66-80.
-
Li Q, Dai Y, Wang F, Hou S: Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma 2016;63:977-983.
-
Huang C, Yu Z, Yang H, Lin Y: Increased MALAT1 expression predicts poor prognosis in esophageal cancer patients. Biomed Pharmacother 2016;83:8-13.
-
Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT: Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell 2016;164:69-80.
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
-
Hu J, Nyren O, Wolk A, et al.: Risk factors for oesophageal cancer in northeast China. Int J Cancer 1994;57:38-46.
-
Sugihara H, Ishimoto T, Miyake K, Izumi D, Baba Y, Yoshida N, Watanabe M, Baba H: Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci 2015;16:27824-27834.
-
Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, Sun N, Liu Z, Skogerboe G, Dong J, Yao R, Zhao Y, Sun J, Zhang B, Yu Y, Shi X, Luo M, Shao K, Li N, Qiu B, Tan F, Chen R, He J: LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut 2014;63:1700-1710.
-
Tong YS, Zhou XL, Wang XW, Wu QQ, Yang TX, Lv J, Yang JS, Zhu B, Cao XF: Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med 2014;12:233.
-
Sun J, Ding C, Yang Z, Liu T, Zhang X, Zhao C, Wang J: The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J Transl Med 2016;14:42.
-
Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, Zhang G, Tian Y, Chen R, Fan Z: The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 2015;16:413-425.
-
Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013;45:1392-1398.
-
Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JA, Elkon R, Agami R: A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol 2010;12:1014-1020.
-
Chen D, Zheng W, Lin A, Uyhazi K, Zhao H, Lin H: Pumilio 1 suppresses multiple activators of p53 to safeguard spermatogenesis. Curr Biol 2012;22:420-425.
Article / Publication Details
Received: January 24, 2017
Accepted: February 24, 2017
Published online: May 10, 2017
Issue release date: June 2017
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 2
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission